Pulmonology Medical News about Pulmonary Disease, Chronic Obstructive

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Biomarkers in Chronic Obstructive Pulmonary Disease
Proceedings of the American Thoracic Society, 09/17/09

Sin DD et al. – Currently, with exception of lung function tests, there are no well validated biomarkers or surrogate endpoints that can be used to establish efficacy of novel drugs for chronic obstructive pulmonary disease (COPD). However, the lung function test is not an ideal surrogate for short–term drug trials because it does not provide information regarding disease activity or the underlying pathologic process, cannot separate the various phenotypes of COPD, is not specific for COPD, and is relatively unresponsive to known therapies that prolong survival. Accordingly, there are large–scale studies presently underway to identify novel biomarkers in COPD.

<< Previous
Sepsis, Mechanical Ventilation, Occupational and Environmental...

Next >>
Lung Transplantation in Patients with Cystic Fibrosis